James Love's blog

32 Members of US House of Representatives ask USTR to sanction Canada for not granting patents on drugs

The attached letter, dated April 10, 2014 and signed by a bipartisan group of 32 members of the House of Representatives, asks USTR to elevate Canada to the Special 301 "priority watch list," for "violation of their international obligations" for not granting enough patents on "innovative medicines." According to the members of Congress signing the letter, Canada is in violation of its WTO TRIPS obligations.

KEI comment on ViiV license to Medicines Patent Pool for HIV drug dolutegravir (DTG)

On April 1, 2014, ViiV, a consortium of Pfizer and GSK, and the Medicines Patent Pool (MPP), announced two new licensing agreements that expand generic competition for dolutegravir (DTG), and integrase inhibitor used for the treatment of adult and pediatric HIV infection. (MPP press release here.) Dolutegravir is a new drug, approved for marketing by the US FDA on August 12, 2013.

EU proposals for TTIP, TRADE IN SERVICES, INVESTMENT AND E-COMMERCE, July 2, 2013

ZEIT ONLINE has published the EU's July 2, 2013 proposals for TRADE IN SERVICES, INVESTMENT AND E-COMMERCE in the TTIP negotiation. A copy of the proposal is available here. Tags: ISDS, TTIP

TRADE IN SERVICES, INVESTMENT AND E-COMMERCE
Chapter I General provisions
Chapter II Investment
Chapter III Cross border supply of services

Revised agenda for Feb 24 USTR Special 301 hearing

Here is the REVISED agenda for the Special 301 hearing on February 24. Public Citizen has been added to the list of witnesses, and USTR now lists the names of the speakers for the various trade associations. Unlike recent years, the level of participation by major trade organizations is significant.

SPECIAL 301 PUBLIC HEARING
February 24, 2014 – 10:00 a.m.

Office of the United States Trade Representative
1724 F Street, NW
Washington, D.C. 20508

The Special 301 Hearing is open to the public. Members of the press are welcome to attend.

Alliance for Fair Trade with India (AFTI): Ground zero for trade sanctions against India

The Alliance for Fair Trade with India (AFTI) was created in June 2013, to lobby for "increased action to address the erosion of intellectual property rights ("IPR") in India." According to the group, it is "comprised of organizations representing a range of U.S. industries adversely impacted by India's troubling and frequently discriminatory policies, including manufacturing, agriculture, telecommunications, pharmaceuticals and beyond."

NFTC, a US trade association, asks USTR to sanction China for issuing and enforcing "junk patents" (2014 submission)

A February 7, 2014 Special 301 submission from the National Foreign Trade Council (NFTC) asks USTR to bring trade sanctions against China for granting and enforcing "junk patents." The NFTC also wants patent enforcement to be strickly a private civil remedy (Contrast to the USTR demands that countries implement linkage between drug registration and patents), and complains about China rules that would require employers to more fairly compensation the Chinese inventors they

KEI files comments with USTR on 2014 Special 301

Attached in the February 7, 2014, KEI Special 301 Submission.

KEI was a web page with more context on the Special 301 reports, including links to several submissions, and all Special 301 Reports from 1989 to 2013 (all that exist), here: http://keionline.org/ustr/special301

HAI and Medicus Mundi statements at WHO EB on CEWG demonstration projects

Three NGOs, Medicus Mundi International, HAI and MSF, each read statements during the EB discussions on the CEWG demonstration projects. The statements were limited to 300 words, and NGOs were required to provide the text 24 hours before the agenda item, and obtain WHO approval of the content. KEI worked with HAI on its statement, and the Peoples Health Movement worked with MMI on its statement. The text of the HAI and MMI statements follow:

Health Action International (HAI) statement to EB 134 On agenda item 9.3, follow up to CEWG on financing and coordination

Bayer CEO Marijn Dekkers explains: Nexavar cancer drug is for "western patients who can afford it.”

dr-dekkers_280_en.jpg
Bayer CEO Marijn Dekkers called the Nexavar compulsory license “essentially theft.”

[UPDATE: The latest blog and transcript of Bayer CEO Marijn Dekkers' full quote on the Indian compulsory license of Nexavar at the December Financial Times event is now available.]

New leaked Merck missive reveals deep drug, medical device company opposition to South African patent reforms

James K Glassman
James K. Glassman. Merck said Glassman's public relations firm was selected by PhRMA to lead a campaign to keep drug prices high in South Africa. The Health Minister in South Africa referred to the campaign proposal as a genocidal conspiracy of satanic magnitude.

KEI testimony on WIPO broadcasting treaty, to House Judiciary Subcommittee on Courts, Intellectual Property, and Internet

Testimony of James Packard Love
Hearing on: The Scope of Copyright Protection
January 14, 2014
Subcommittee on Courts, Intellectual Property, and the Internet

My 10 page written statement is here: http://keionline.org/sites/default/files/JamesLove_Testimony.pdf

My 5 minute oral statement follows:

James Packard Love, Opening statement

Hearing on: The Scope of Copyright Protection
January 14, 2014
Subcommittee on Courts, Intellectual Property, and the Internet

Fast track trade bill fails to correct asymmetric secrecy of trade negotiations

Today Senators Bacus and Hatch introduced fast track legislation in the Senate. The words transparent or transparency appear 17 times in the 107 page bill, but only twice in connection with "Trade Institution Transparency."

USPTO 2013 utility patent grants (notes on country of assignment, invention class, government rights in patents)

In 2013, the USPTO issued 277,861 utility patents, a new record in terms of the numbers of patent grants, and an increase of 9.8 percent over 2012.*

Country of Assignment

Of the total, 126,574 (45.6 percent) were assigned to a US owner, a small increase in the percent held by US entities over 2012.

Final conclusions, as approved, for meeting of WIPO SCCR 26

Below is the final version of the conclusions from SCCR 26 (followed at the end with a short KEI commentary).


------------
World Intellectual Property Organization (WIPO)
Standing Committee on Copyright and Related Rights (SCCR)
Twenty–sixth Session
Geneva, December 20, 2013

Conclusions

Protection of Broadcasting Organizations

Proposed conclusions to SCCR 26

See PDF attachment. Note that PDF has pages 2 and 3 out of order.

Syndicate content